Stockscreener 앱 받기
1,017.09
0.60%
-4.3201
전일 마감가:
$1,021.41
열려 있는:
$1024.99
하루 거래량:
1.84M
Relative Volume:
0.61
시가총액:
$905.63B
수익:
$72.25B
순이익/손실:
$25.28B
주가수익비율:
36.61
EPS:
27.781
순현금흐름:
$10.37B
1주 성능:
-0.04%
1개월 성능:
+10.37%
6개월 성능:
-2.68%
1년 성능:
+35.92%
1일 변동 폭
$1,003.69
$1,037.88
1주일 범위
$978.87
$1,037.88
52주 변동 폭
$623.78
$1,133.95
일라이 릴리 Stock (LLY) Company Profile
명칭
Lilly Eli Co
전화
(317) 276-2000
주소
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,015.58 | 881.12B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
229.65 | 551.06B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
213.17 | 369.98B | 62.82B | 3.60B | 19.98B | 2.0274 |
AZN
Astrazeneca Plc
|
187.35 | 285.23B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
150.58 | 284.59B | 54.66B | 13.58B | 16.05B | 7.0171 |
일라이 릴리 Stock (LLY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-17 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2026-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-12-16 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | 재확인 | BofA Securities | Buy |
| 2025-12-15 | 재확인 | Goldman | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-11-10 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | 재확인 | BMO Capital Markets | Outperform |
| 2025-10-14 | 업그레이드 | Erste Group | Hold → Buy |
| 2025-09-17 | 다운그레이드 | Berenberg | Buy → Hold |
| 2025-08-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2025-08-18 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-09-13 | 재개 | Citigroup | Buy |
| 2024-08-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-02-21 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2024-02-16 | 재확인 | Morgan Stanley | Overweight |
| 2023-12-21 | 다운그레이드 | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-20 | 재개 | UBS | Buy |
| 2023-08-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-26 | 재확인 | Citigroup | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-24 | 재확인 | BofA Securities | Buy |
| 2023-05-24 | 재확인 | UBS | Buy |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-15 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-09-22 | 업그레이드 | UBS | Neutral → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-03-10 | 개시 | Daiwa Securities | Outperform |
| 2022-01-21 | 업그레이드 | DZ Bank | Hold → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-16 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-16 | 재확인 | BofA Securities | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-11 | 업그레이드 | Berenberg | Hold → Buy |
| 2021-09-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-05 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-06-24 | 재확인 | Cantor Fitzgerald | Overweight |
| 2021-01-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-12-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-09-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2019-12-18 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-04-24 | 업그레이드 | Edward Jones | Hold → Buy |
| 2019-04-11 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-03-12 | 개시 | JP Morgan | Overweight |
| 2019-01-23 | 개시 | UBS | Buy |
| 2018-11-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-10-01 | 재확인 | SunTrust | Buy |
| 2018-09-26 | 재개 | JP Morgan | Overweight |
모두보기
일라이 릴리 주식(LLY)의 최신 뉴스
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio - Pharmaceutical Executive
ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsight - GlobeNewswire Inc.
Li Lilly (LLY) Files Lawsuit Over $200 Million Drug Rebate Fraud - GuruFocus
Engage Bio Acquired by Lilly to Accelerate Development of Non-Viral Genetic Medicines - PharmiWeb.com
Eli Lilly (LLY) Acquires Engage Biologics for Up to $202M - GuruFocus
Eli Lilly and Co (LLY) Stock Price, Trades & News - GuruFocus
Eli Lilly accuses church bishops, businessmen of fraud in Trulicity drug rebate scheme - CNBC
Eli Lilly (LLY) Acquires Engage Biologics for $202 Million - TipRanks
Lilly Acquires Engage Bio in Push to Expand Non-Viral Genetic Medicine Capabilities - citybiz
Eli Lilly Expands TuneLab Access As AI Partnerships Shape R&D Outlook - Yahoo Finance
Eli Lilly (LLY) Acquires Engage Biologics for Up to $202 Million - GuruFocus
Press Release: Engage Bio Acquired by Lilly to Accelerate Development of Non-Viral Genetic Medicines - 富途牛牛
Eli Lilly stock (US5324571083): obesity and diabetes portfolio drive fresh attention after latest ap - AD HOC NEWS
Eli Lilly & Co. stock (US5324571083): Recent catalyst to watch - AD HOC NEWS
Eli Lilly and Co (LLY) Shares Surge 3.4% -- What GF Score of 98 Tells Investors - GuruFocus
Eli Lilly shares bought on Trump’s behalf as his policies benefited drug firm - The Guardian
Eli Lilly stock (US5324571083): blockbuster obesity drugs keep growth story in focus - AD HOC NEWS
Trump's Stock Picks Perfectly Timed With New Medicare Rules: Report - Benzinga
President Trump Bought Eli Lilly Stock (LLY) as Government Approved Weight-Loss Pill - TipRanks
A new ranking of pharma companies by R&D performance - statnews.com
Trump bought stock in drugmaker as his government boosted its obesity drugs - Fierce Pharma
Citi Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,500 - 富途牛牛
Eli Lilly tops prominent rankings on pharma R&D performance - statnews.com
Eli Lilly stock (US5324571083): weight-loss boom drives Q1 2026 earnings jump - AD HOC NEWS
Eli Lilly Is A Buy (Technical Analysis) - Seeking Alpha
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party - The Motley Fool
Eli Lilly Stock: Next Stop $2,000? - AOL.com
Eli Lilly (LLY) Supreme Court Challenge Dismissed, $183 Million Judgment Stands - GuruFocus
US Supreme Court turns away Eli Lilly’s challenge to whistleblower law - The Journal Record
Supreme Court Rejects Eli Lilly Appeal In Medicaid Fraud CaseEli Lilly (NYSE:LLY) - Benzinga
Justices Deny Eli Lilly's Qui Tam Constitutional Challenge - Law360
Lilly rebuffed by Supreme Court on $194M Medicaid award - The Indiana Lawyer
Eli Lilly to Attend Bernstein Annual Strategic Decision Conferen - GuruFocus
Eli Lilly Makes Another Biotech Bet Ahead Of Retatrutide Data – LLY Stock Surges To Highest In Over 2 Months - Stocktwits
Eli Lilly (LLY) Supreme Court Ruling Leaves Lower Court Decision Intact - GuruFocus
Eli Lilly Among Petitioners Denied Certiorari as Supreme Court Rejects Multiple Appeals - Moomoo
Supreme Court rejects Eli Lilly challenge to Civil War era law on Medicaid fraud - The Independent
Eli Lilly (LLY) Dealt Blow as U.S. Supreme Court Refuses to Hear Whistleblower Law Challenge - TipRanks
US Supreme Court turns away Eli Lilly's challenge to whistleblower law - Reuters
US Supreme Court turns away Eli Lilly’s challenge to whistleblower law By Reuters - Investing.com
Eli Lilly loses Supreme Court appeal of $194 million fraud award - Investing.com Canada
Lilly's Daniel Skovronsky joins Bernstein fireside chat on May 28 - Stock Titan
Lilly Rebuffed by Supreme Court on $194 Million Medicaid Award - Bloomberg
Trump bought stock in drugmaker Eli Lilly as his government boosted its obesity drugs - Tucson Sentinel
Novo Nordisk's Wegovy pill maintains strong lead over Eli Lilly rival despite weekly dip, Citi says - Proactive Investors
Harbour posts preclinical data on would-be rival to Eli Lilly’s $1.9B obesity bet - European Biotechnology Magazine
LLY: Eli Lilly & Co. Passes the Affordable Growth (GARP) Screen with Strong Momentum and Fair Valuation - ChartMill
Eli Lilly & Co stock (US5324571083): Q1 2026 earnings beat underscores obesity and diabetes momentum - AD HOC NEWS
Eli Lilly and Company $LLY Shares Acquired by Sapient Capital LLC - MarketBeat
North Dakota State Investment Board Purchases Shares of 27,482 Eli Lilly and Company $LLY - MarketBeat
Passumpsic Savings Bank Takes Position in Eli Lilly and Company $LLY - MarketBeat
일라이 릴리 (LLY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.26%
1.21%
자본화:
|
볼륨(24시간):